International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update
Seth J. Rotz,Neel S. Bhatt,Betty K. Hamilton,Christine Duncan,Mahmoud Aljurf,Yoshiko Atsuta,Kristen Beebe,David Buchbinder,Peggy Burkhard,Paul A. Carpenter,Naeem Chaudhri,Mohamed Elemary,Mahmoud Elsawy,Gregory M. T. Guilcher,Nada Hamad,Amado Karduss,Zinaida Peric,Duncan Purtill,Douglas Rizzo,Morgani Rodrigues,Maria Belén Rosales Ostriz,Nina Salooja,Helene Schoemans,Adriana Seber,Akshay Sharma,Alok Srivastava,Susan K. Stewart,K. Scott Baker,Navneet S. Majhail,Rachel Phelan
DOI: https://doi.org/10.1038/s41409-023-02190-2
2024-02-27
Bone Marrow Transplantation
Abstract:As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the volume of HCT performed annually continues to rise. Parallel improvements in HCT techniques and supportive care entails more patients surviving long-term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary to pre-, peri- and post-transplant exposures and other underlying risk-factors. Guidelines for screening and preventive practices for HCT survivors were originally published in 2006 and updated in 2012. To review contemporary literature and update the recommendations while considering the changing practice of HCT and cellular therapy, an international group of experts was again convened. This review provides updated pediatric and adult survivorship guidelines for HCT and cellular therapy. The contributory role of chronic graft-versus-host disease (cGVHD) to the development of late effects is discussed but cGVHD management is not covered in detail. These guidelines emphasize special needs of patients with distinct underlying HCT indications or comorbidities (e.g., hemoglobinopathies, older adults) but do not replace more detailed group, disease, or condition specific guidelines. Although these recommendations should be applicable to the vast majority of HCT recipients, resource constraints may limit their implementation in some settings.
oncology,immunology,hematology,transplantation